Xenon Pharmaceuticals Inc. — Director's Dealing 2018

Jun 5, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2018-06-04

Reporting Person: Hayden Michael R (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-04	Stock Option (Right to Buy)	$6.20	A	15000	Acquired	2028-06-03	Common Shares (15000)	Direct

Footnotes

F1: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date.